Health

  • December 22, 2025

    6th Circ. Vacates Pharma Salesman's $6.8M Restitution Order

    The Sixth Circuit vacated a nearly $7 million restitution order against a pharmaceutical salesman convicted of healthcare fraud, finding an Ohio federal court erred in calculating that amount and apportioning liability.

  • December 22, 2025

    Ed Dept. Ordered To Restore $1B In Mental Health Grants

    The U.S. Department of Education will not be allowed to cut more than $1 billion in mental health grants for schools after a Washington federal judge ruled that the agency acted illegally by citing new, undisclosed Trump administration priorities as a basis for slashing the funding.

  • December 22, 2025

    New Class Action Claims CIBC, RBC Rigged Quantum Shares

    A Quantum Biopharma investor has filed a proposed class action against several major Canadian banks, accusing them of running a spoofing scheme for years that artificially drove down Quantum's stock price — flooding exchanges with fake sell orders to mislead the market and buy shares at deflated prices, costing ordinary shareholders millions.

  • December 19, 2025

    J&J Hit With $66M Verdict In Minnesota Mom's Asbestos Case

    A Minnesota jury Friday awarded a mother of three $65.5 million following a 13-day trial in her lawsuit that claimed Johnson & Johnson's talc products exposed her to asbestos and contributed to cancer in her abdominal lining, the mother's attorneys announced.

  • December 19, 2025

    Feds Fight 'Do-Over' Of Tort Atty's Attempted-Extortion Rap

    Federal prosecutors are urging the Fourth Circuit not to give "a do-over" to a medical malpractice attorney who was convicted of attempting to extort the University of Maryland Medical System out of $25 million and who says his self-representation at trial was not competent.

  • December 19, 2025

    Trump's Cannabis Order: The Impact On Hemp And Research

    President Donald Trump's executive order Thursday reignited an administrative process to reclassify marijuana as a less restricted drug, but its provisions touching on cannabis research and hemp-derived CBD are less obvious.

  • December 19, 2025

    Health Co. CEO Gets 15 Years In $1.4B Fraud Scheme

    A Florida federal judge sentenced a software company CEO to 15 years in prison Friday for participating in a scheme to coordinate illegal medical kickbacks through an internet platform, an operation that resulted in $1.4 billion worth of false billings to Medicare and other insurers for unnecessary medical products.

  • December 19, 2025

    Michigan's 5 Biggest Court Rulings Of 2025

    Michigan courts had a memorable year in 2025, issuing rulings that extended protections against automatic life sentences to young adults, struck down abortion restrictions and pulled the plug on criminal cases related to President Donald Trump's so-called fake elector plot.

  • December 19, 2025

    AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

    A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly propped up blood disorder treatment Soliris, while preserving accusations that Alexion brought sham infringement allegations against would-be rivals.

  • December 19, 2025

    Squires Issues 21 More Patent Review Denials

    U.S. Patent and Trademark Office Director John Squires has denied 21 requests for America Invents Act patent reviews, while not agreeing to institute any new proceedings.

  • December 19, 2025

    Medical, School Groups Seek Order Halting $100K Visa Fee

    A medical practice in rural North Carolina and other employers asked a federal judge Friday to block enforcement of the Trump administration's $100,000 fee on H-1B visas, arguing the "massive" fee hike will inflict irreparable harm on their communities.

  • December 19, 2025

    Florida Supreme Court To Review Pot Legalization Effort

    The Florida Supreme Court has agreed to weigh whether a new proposal to legalize retail marijuana via ballot initiative complies with the state's constitution.

  • December 19, 2025

    BigLaw And Boutiques Both Shine In 2025's Top 10 Deals

    A tight circle of elite law firms guided the way as megadeals roared back with force in 2025, while a small group of specialist and international firms also made their mark across global transactions spanning infrastructure, gaming, pharmaceuticals, artificial intelligence and energy.

  • December 19, 2025

    Taxation With Representation: Baker Botts, Morgan Lewis

    In this week's Taxation With Representation, Trump Media and Technology Group merges with fusion power company TAE Technologies, pharmaceutical company Cencora boosts its stake in cancer care company OneOncology, and Phoenix Financial partners with private equity giant Blackstone to plug billions into various credit strategies.

  • December 19, 2025

    Hospital Knocks Discharge Claim From EEOC Sex Bias Suit

    An Arkansas federal judge agreed to cut the constructive discharge allegation from a U.S. Equal Employment Opportunity Commission lawsuit alleging two doctors at an Arkansas hospital refused to let a male medical assistant help with childbirth, noting that the worker assisted with other deliveries.

  • December 19, 2025

    Trump Admin Appeals Harvard Win In $2B Fund Freeze Case

    The Trump administration will ask the First Circuit to overturn a federal judge's ruling that prevented the government from withholding $2.2 billion in federal grants from Harvard University over concerns about antisemitism on campus.

  • December 19, 2025

    The 6 Biggest Rulings By Massachusetts' Top Court In 2025

    Massachusetts' top court rejected a novel double jeopardy claim in a headline-grabbing murder case, revived claims against Harvard over a "ghoulish" scheme, and said a Snapchat Bitmoji could show police bias, among other significant rulings this year.

  • December 19, 2025

    UK Litigation Roundup: Here's What You Missed In London

    This past week in London has seen the designer of an 88-facet diamond bring a copyright claim against a luxury watch retailer, collapsed firm Axiom Ince bring legal action against the solicitors' watchdog, and the Post Office hit with compensation claims from two former branch managers over their wrongful convictions during the Horizon information technology scandal.

  • December 19, 2025

    BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved

    BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until 2037, the companies said Friday.

  • December 18, 2025

    The Biggest Rulings From A Busy Year At The 1st Circ.

    The nation's smallest federal appellate panel punched above its weight in 2025, grappling with numerous suits against the Trump administration, high-profile criminal appeals, a $34 million legal fee bid and a hotly contested kickback law.

  • December 18, 2025

    Trump Order Rallies Cannabis Industry, Advocates Want More

    The executive order signed by President Donald Trump on Thursday, marking the most substantial shift in federal cannabis policy in over half a century, is expected to have favorable ramifications for the marijuana industry even as it falls short of decriminalizing the drug or resolving the many tensions between federal and state law.

  • December 18, 2025

    Split 6th Circ. Blocks Michigan's Ban On Conversion Therapy

    A split Sixth Circuit panel ordered an injunction on Michigan's conversion therapy ban, ruling the law likely places an unconstitutional restriction on the First Amendment rights of a Catholic charitable organization and a therapist whose faith-based psychotherapy practices fall under the ban.

  • December 18, 2025

    InnovAge Investors Get Final OK For $27M Deal, Atty Fees

    A Colorado federal judge has granted final approval to a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior healthcare company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the alleged falsehoods.

  • December 18, 2025

    Medical Supplier Gets Prison For $7.8M Healthcare Fraud

    A Connecticut man who admitted to conspiring to rip off Medicare, the military health program Tricare and private insurers has been ordered to serve 2½ years in federal prison and to immediately pay nearly $7.9 million in restitution.

  • December 18, 2025

    Doctors Freed From Suit As NC Panel Deems It MedMal Issue

    Parents whose young daughter died following complications from heart surgery can't revive their lawsuit against pediatric heart doctors because their fraud and breach of fiduciary duty claims "sounded in" medical malpractice and were thus barred, a North Carolina state appeals court panel said Wednesday.

Expert Analysis

  • When AI Denies, Insurance Bad Faith Claims May Follow

    Author Photo

    Two recent rulings from Minnesota and Kentucky federal courts signal that past statements about claims-handling practices may leave insurers using artificial intelligence programs in claims administration vulnerable to suits alleging bad faith and unfair trade practices, say attorneys at Cozen O'Connor.

  • Health Insurance Kickback Cases Signal Greater Gov't Focus

    Author Photo

    A series of recent indictments by federal prosecutors in California suggests that the Eliminating Kickbacks in Recovery Act is gaining momentum as an enforcement tool against illegal inducement of patient referrals in the realm of commercial health insurance, say attorneys at BakerHostetler.

  • FDA Transparency Plans Raise Investor Disclosure Red Flags

    Author Photo

    The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Demystifying The Civil Procedure Rules Amendment Process

    Author Photo

    Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.

  • With Obligor Ruling, Ohio Justices Calm Lending Waters

    Author Photo

    A recent decision by the Ohio Supreme Court, affirming a fundamental principle that lenders have no duty to disclose material risks to obligors, provides clarity for commercial lending practices in Ohio and beyond, and offers a reminder of the risks presented by guarantee arrangements, says Carrie Brosius at Vorys.

  • How 2nd Circ. Cannabis Ruling Upends NY Licensing

    Author Photo

    A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.

  • Parenting Skills That Can Help Lawyers Thrive Professionally

    Author Photo

    As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.

  • Series

    Teaching Trial Advocacy Makes Us Better Lawyers

    Author Photo

    Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.

  • Federal AI Action Plan Marks A Shift For Health And Bio Fields

    Author Photo

    The Trump administration's recent artificial intelligence action plan significantly expands federal commitments across biomedical agencies, defining a pivotal moment for attorneys and others involved in research collaborations, managing regulatory compliance and AI-related intellectual property, says Mehrin Masud-Elias at Arnold & Porter.

  • Preparing For DEA Rescheduling Of 2 Research Chemicals

    Author Photo

    A recent decision to allow the U.S. Drug Enforcement Administration to reclassify two research psychedelics in Schedule I under the Controlled Substances Act may pose significant barriers to scientific study, including stringent registration requirements, heightened security protocols and burdensome reporting obligations, say Kimberly Chew at Husch Blackwell and Jackie von Salm at Psilera.

  • Series

    Adapting To Private Practice: From Texas AUSA To BigLaw

    Author Photo

    As I learned when I transitioned from an assistant U.S. attorney to a BigLaw partner, the move from government to private practice is not without its hurdles, but it offers immense potential for growth and the opportunity to use highly transferable skills developed in public service, says Jeffery Vaden at Bracewell.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.